Precigen (NASDAQ:PGEN) CEO Helen Sabzevari Sells 346,836 Shares

Precigen, Inc. (NASDAQ:PGEN) CEO Helen Sabzevari sold 346,836 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the transaction, the chief executive officer owned 3,768,872 shares of the company’s stock, valued at approximately $22,198,656.08. This represents a 8.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Sabzevari also recently made the following trade(s):

• On Thursday, May 28th, Helen Sabzevari sold 119,250 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $519,930.00.

Precigen Stock Down 7.9%

Shares of NASDAQ:PGEN traded down $0.45 during midday trading on Wednesday, hitting $5.25. The stock had a trading volume of 7,446,304 shares, compared to its average volume of 4,558,847. The business’s 50-day simple moving average is $4.40 and its 200-day simple moving average is $4.21. Precigen, Inc. has a 12 month low of $1.45 and a 12 month high of $6.04. The company has a market cap of $1.87 billion, a P/E ratio of -4.45 and a beta of 1.06. The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $23.25 million for the quarter, compared to analysts’ expectations of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. On average, sell-side analysts forecast that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PGEN has been the subject of several research analyst reports. HC Wainwright lifted their target price on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Citizens Jmp raised their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Finally, Zacks Research upgraded Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $12.50.

Institutional Trading of Precigen

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its position in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,426 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Precigen by 61.0% in the first quarter. The Manufacturers Life Insurance Company now owns 90,143 shares of the biotechnology company’s stock valued at $349,000 after buying an additional 34,137 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Precigen during the first quarter worth approximately $1,531,000. State of Wyoming acquired a new stake in Precigen during the first quarter worth approximately $27,000. Finally, Cetera Investment Advisers increased its stake in Precigen by 0.9% during the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after acquiring an additional 3,250 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.